Table 1 Demographic information and cohort of HPV-negative OPSCC patients (n = 124)
Variable | In total | SND with I-III (n = 62) | SND with I-IV (n = 62) | P | |
|---|---|---|---|---|---|
n (%) | |||||
Age, yr | 60.7 ± 12.0a | 60.9 ± 11.3a | 60.5 ± 11.7a | 0.823b | |
Sex, female | 17 (13.7) | 6 (9.7) | 11 (17.7) | 0.296c | |
Subsite | Base of tongue | 94 (75.9) | 47 (75.9) | 47 (75.9) | 1.000c |
Soft palate | 22 (17.7) | 11 (17.7) | 11 (17.7) | ||
Tonsil | 6 (4.8) | 3 (4.8) | 3 (4.8) | ||
Pharyngeal walls | 2 (1.6) | 1 (1.6) | 1 (1.6) | ||
T stage | T1 | 15 (12.1) | 7 (11.3) | 8 (12.9) | 0.991c |
T2 | 36 (29.0) | 18 (29.0) | 18 (29.0) | ||
T3 | 46 (37.1) | 23 (37.1) | 23 (37.1) | ||
T4 | 27 (21.7) | 14 (22.3) | 13 (21.0) | ||
N stage | N0 | 76 (61.3) | 36 (58.1) | 40 (64.5) | 0.750c |
N1 | 28 (22.6) | 14 (22.6) | 14 (22.6) | ||
N2 | 16 (12.9) | 10 (16.1) | 6 (9.7) | ||
N3 | 4 (3.2) | 2 (3.2) | 2 (3.2) | ||
Radiotherapy | 61 (49.2) | 32 (51.6) | 29 (46.8) | 0.590c | |
Chemoradiotherapy | 20 (16.1) | 11 (17.7) | 9 (14.5) | 0.625c | |